Agenus Inc.: Neoplasms trials
The registry lists 11 Neoplasms studies with Agenus Inc. as lead sponsor. 1 are open to participants now and 0 have results posted.
Phase 1 9Phase 2 4No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)AvailableNCT05572970
- Study of AGEN1571 in Participants With Advanced Solid TumorsCompletedNCT05377528Phase 1
- A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid TumorsCompletedNCT05108623Phase 1
- A Study in Subjects With Advanced Solid TumorsTerminatedNCT04156100Phase 1
- Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced CancerCompletedNCT04121676Phase 1
- Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced CancerTerminatedNCT02992977Phase 1
- Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell LymphomaCompletedNCT00316511Phase 1
- Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard TherapiesStatus unknownNCT00081549Phase 1/2
- Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard TherapiesStatus unknownNCT00081536Phase 1/2
- A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid MalignanciesStatus unknownNCT00057395Phase 1/2
- A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard TherapiesStatus unknownNCT00043199Phase 2